These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10498572)

  • 1. Hemochromatosis and vitamin C.
    Herbert V
    Ann Intern Med; 1999 Sep; 131(6):475-6. PubMed ID: 10498572
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
    Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L
    Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 4. [The treatment of post-transfusional hemochromatosis with chelating agents].
    Delvaux D; Andrien JM; Fillet G
    Rev Med Liege; 1981 Jun; 36(11):477-80. PubMed ID: 6789438
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 6. Chelation therapy for iron overload.
    Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885
    [No Abstract]   [Full Text] [Related]  

  • 7. Vitamin C, desferrioxamine and iron loading anemias.
    Van der Weyden MB
    Aust N Z J Med; 1984 Oct; 14(5):593-5. PubMed ID: 6597704
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hemochromatosis in the age of genetics].
    Buffet C
    Presse Med; 2007 Sep; 36(9 Pt 2):1269-70. PubMed ID: 17560763
    [No Abstract]   [Full Text] [Related]  

  • 9. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 10. [Idiopathic hemochromatosis. Therapeutics].
    Pergola F
    Presse Med (1893); 1967 May; 75(24):1221-2. PubMed ID: 4960744
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of primary hemochromatosis with deferoxamine.
    Young N; Henry W; Nienhuis AW
    JAMA; 1979 Mar; 241(11):1152-4. PubMed ID: 762769
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis.
    Conte D; Brunelli L; Ferrario L; Mandelli C; Quatrini M; Velio P; Bianchi PA
    Acta Haematol; 1984; 72(2):117-20. PubMed ID: 6437113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies.
    Sigurdsson L; Reyes J; Kocoshis SA; Hansen TW; Rosh J; Knisely AS
    J Pediatr Gastroenterol Nutr; 1998 Jan; 26(1):85-9. PubMed ID: 9443126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal hemochromatosis: failure of deferoxamine therapy.
    Jonas MM; Kaweblum YA; Fojaco R
    J Pediatr Gastroenterol Nutr; 1987; 6(6):984-8. PubMed ID: 3681586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion.
    Wapnick AA; Lynch SR; Charlton RW; Seftel HC; Bothwell TH
    Br J Haematol; 1969 Dec; 17(6):563-8. PubMed ID: 5357744
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biologically active hydroxamic acids--iron complexons].
    Kol'tsova GN; Mel'nikovskaia NN; Likhodzievskiĭ KG; Rozenberg GIa
    Gematol Transfuziol; 1984 Sep; 29(9):56-9. PubMed ID: 6394425
    [No Abstract]   [Full Text] [Related]  

  • 17. Chelating agents in medicine.
    Br Med J; 1971 May; 2(5756):270-2. PubMed ID: 4102017
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

  • 19. Ascorbic acid status in idiopathic hemochromatosis.
    Brissot P; Deugnier Y; Le Treut A; Regnouard F; Simon M; Bourel M
    Digestion; 1978; 17(6):479-87. PubMed ID: 710734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemochromatosis and iron chelating therapy].
    Hershko C; Link AG; Pinson A; Grisaru S; Sarel S; Grady RW
    Harefuah; 1986 Nov; 111(10):336-8. PubMed ID: 3546013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.